Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease non-cystic fibrosis bronchiectasis (NFCB).

Intervention/Treatment: The trial tests Itepekimab, administered subcutaneously in high and low doses, alongside Mometasone furoate nasal spray. The purpose is to improve symptoms in patients with ...

MS Pharma & Kashiv Biosciences enter licensing and supply pact for commercialization of ADL-018/bOmalizumab in the MENA region: Jordan Thursday, August 7, 2025, 11:00 Hrs [IST] MS ...

Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis ...

Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in ...

If AZ has to wait for the results of that second trial it will allow Dupixent to consolidate its position, and perhaps more significantly for Fasenra's prospects in CRSwNP allow Nucala to build ...

The committee recalled the potential uncaptured benefits related to the lack of sensitivity of the EQ-5D in severe CRSwNP, and the potential for dupilumab to reduce the need for oral corticosteroids ...